Zydus Lifesciences receives USFDA approval for Empagliflozin Tablets

4 Aug 2022 , 12:02 PM

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to market Empagliflozin Tablets USP 10 mg and 25 mg. USRLD: Jardiance. Empagliflozin is used to lower blood sugar levels in people with type 2 diabetes. It is also used to reduce the risk of stroke, heart attack, or death in people with type 2 diabetes along with heart and blood vessel disease. The drug will be manufactured at the groups formulation manufacturing facility at Ahmedabad SEZ, India. Empagliflozin Tablets had annual sales of USD 9,810 million in the United States according to IQVIA data (IQVIA MAT June 2022). Powered by Capital Market – Live News